These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15648966)
21. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Ridker PM; Cook N Circulation; 2004 Apr; 109(16):1955-9. PubMed ID: 15051634 [TBL] [Abstract][Full Text] [Related]
22. High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes. Lorenzová A; Stanek V; Gebauerová M; Bohuslavová R; Stávek P; Hubácek JA; Lánská V; Poledne R Clin Chem Lab Med; 2007; 45(7):855-61. PubMed ID: 17617027 [TBL] [Abstract][Full Text] [Related]
23. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085 [TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of high sensitivity C-reactive protein in cardiology. Adukauskienė D; Čiginskienė A; Adukauskaitė A; Pentiokinienė D; Šlapikas R; Čeponienė I Medicina (Kaunas); 2016; 52(1):1-10. PubMed ID: 26987494 [TBL] [Abstract][Full Text] [Related]
25. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Ridker PM Circulation; 2001 Apr; 103(13):1813-8. PubMed ID: 11282915 [TBL] [Abstract][Full Text] [Related]
26. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Shen J; Ordovas JM Clin Chem; 2009 Feb; 55(2):256-64. PubMed ID: 19074515 [TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Carter NJ Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831 [TBL] [Abstract][Full Text] [Related]
30. Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. Pirro M; Stingeni L; Vaudo G; Mannarino MR; Ministrini S; Vonella M; Hansel K; Bagaglia F; Alaeddin A; Lisi P; Mannarino E Eur J Prev Cardiol; 2015 Aug; 22(8):1027-35. PubMed ID: 24906366 [TBL] [Abstract][Full Text] [Related]
31. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. Kamath DY; Xavier D; Sigamani A; Pais P Indian J Med Res; 2015 Sep; 142(3):261-8. PubMed ID: 26458341 [TBL] [Abstract][Full Text] [Related]
32. [Assessment of high sensitivity C-reactive protein (HS-CRP) as a marker of liver inflammation in patients with metabolic syndrome]. Rodríguez-Leal GA; Morán S; Gallardo I; Milke P; Guevara-González L Rev Gastroenterol Mex; 2006; 71(1):39-45. PubMed ID: 17063573 [TBL] [Abstract][Full Text] [Related]
33. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR J Hypertens; 2008 Jan; 26(1):26-34. PubMed ID: 18090537 [TBL] [Abstract][Full Text] [Related]
34. Old markers, new approach to assessment of risk in heart failure. Kodziszewska K; Leszek P; Korewicki J; Piotrowski W Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469 [TBL] [Abstract][Full Text] [Related]
35. Comparison of high-sensitivity C-reactive protein serum assay results obtained using Dade-Behring BNII nephelometer and Ortho Vitros FS 5.1 clinical analyzer in respect of CRP-related risk assessment of chronic metabolic diseases. Kusnierz-Cabala B; Gernand W; Zabek-Adamska A; Tokarz A; Naskalski JW Clin Lab; 2008; 54(9-10):341-6. PubMed ID: 19097491 [TBL] [Abstract][Full Text] [Related]
36. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. Duprez DA; Somasundaram PE; Sigurdsson G; Hoke L; Florea N; Cohn JN J Hum Hypertens; 2005 Jul; 19(7):515-9. PubMed ID: 15905893 [TBL] [Abstract][Full Text] [Related]
37. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Wilson AM; Ryan MC; Boyle AJ Int J Cardiol; 2006 Jan; 106(3):291-7. PubMed ID: 16337036 [TBL] [Abstract][Full Text] [Related]
38. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). Hu M; Lee MH; Mak VW; Tomlinson B Am J Cardiol; 2010 Dec; 106(11):1588-93. PubMed ID: 21094359 [TBL] [Abstract][Full Text] [Related]
40. [Prevalence of C-reactive protein levels in adult population in two regions in the czech republic and their relation to body composition]. Cerovská J; Hoskovcová P; Vosátková M; Zamrazilová H; Zamrazil V Vnitr Lek; 2006 Nov; 52(11):1045-50. PubMed ID: 17165523 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]